Autonomic Reactivity and Personalized Neurostimulation
Medical College of Wisconsin · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT06863207
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 11–18 · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 120
- US sites recruiting
- 1
- Study start
- January 24, 2025
- Record last updated
- February 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Disorders of gut-brain interaction (DGBI) affect up to 25% of U.S. children. Patients often suffer from disabling, multisystem comorbidities that suggest a common root (sleep disturbances, fatigue, anxiety, etc). Yet, DGBI are defined and treated based on GI symptom origin (cyclic vomiting, dyspepsia, irritable bowel) rather than underlying pathophysiology. Many patients manifest comorbidities suggesting an underlying autonomic nervous system (ANS) dysregulation (palpitations, dizziness, cognitive dysfunction). Unfortunately, due to common features of anxiety and visceral hyperreactivity and lack of obvious pathology, children with DGBI are frequently diagnosed with psychosomatic or 'benign, functional disorders' and treated with empiric antidepressants despite lack of scientific support and risks of serious side effects. Little is known about the underlying brain-gut mechanisms linking these comorbidities. A lack of targeted treatment options naturally follows the paucity of mechanistic data. A dysregulated ANS response circuit via brainstem nuclei is linked to visceral hypersensitivity. As the team's prior research has shown, ANS regulation can be non-invasively measured via several validated indices of cardiac vagal tone. Using the novel vagal efficiency (VE) metric, the investigators have demonstrated inefficient vagal regulation in cyclic vomiting syndrome and pain-related DGBI and that low VE predicts response to non-invasive, auricular percutaneous electrical nerve field stimulation (PENFS) therapy. PENFS targets brainstem vagal afferent pathways and, along with brain-gut interventions such as hypnotherapy, are the only therapies currently proven effective for pediatric DGBI. Individualizing neurostimulation based on sensory thresholds while assessing dynamic ANS reactivity offers a path towards personalized medicine using the most effective therapies to date. This proposal will test the feasibility of an ANS tracking software in assessing real-time, autonomic regulation and providing individualized neurostimulation in children with nausea/vomiting and ANS imbalance.
Being studied: Percutaneous electrical nerve field stimulation; Hypnotherapy
Conditions: Functional Gastrointestinal Disorders (FGIDs); Cyclic Vomiting Syndrome; Functional Dyspepsia; Dysautonomia
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- 11 to 18 years of age
- English speaking
- meeting Rome IV diagnostic criteria for cyclic vomiting syndrome or functional dyspepsia and willingness to participate and consent/assent to the study
- All subjects will have a constellation of chronic symptoms indicative of autonomic dysfunction for minimum 3 months: postural dizziness/lightheadedness, syncope, palpitations, fatigue, sleep disturbance, thermoregulatory abnormalities and cognitive impairment with upright position +/- abnormal autonomic testing if performed per standard of care as per American Autonomic Society consensus criteria.
Exclusion Criteria
- Presence of organic disease that may explain symptoms
- Requirement for parenteral nutrition
- Developmental delays precluding accurate symptom report
- Severe dermatological condition or active infection of external or middle ear
- Implanted electrical device
- Severe mental health disorder not controlled by therapy (schizophrenia, bipolar disease, severe depression, post-traumatic distress disorder) and/or psychotic features which could influence symptom report or ANS measurements and result in adverse reactions to hypnosis therapy
Recruiting US locations
Medical College of Wisconsin
Milwaukee, WI 53005
Site contact: Lisa Nielson, BS · 414-266-3695 · lnielson@mcw.edu
Study contacts (from the official record)
- Elaina Schueler, BS · 4142663695 · eschueler@mcw.edu
Similar studies in Wisconsin
All healthy volunteers studies in Wisconsin →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How ASP3082 is Processed in Healthy Men
Astellas Pharma Global Development, Inc.
- Location
- Madison, WI
- Eligibility basics
- Ages 18–65 · Men only
- RecruitingHealthy volunteersPhase 1
A Trial of Lu AH69593 in Healthy Participants
H. Lundbeck A/S
- Location
- Madison, WI
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
Ocugen
- Location
- La Crosse, WI + 4 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1
A Trial to Compare the Pharmacokinetics of Two Presentations of Navenibart in Healthy Participants
Astria Therapeutics, Inc.
- Location
- Madison, WI + 2 other US sites
- Eligibility basics
- Ages 18–55